Upfront tandem autologous non‐myeloablative allogeneic stem cell transplant in high‐risk multiple myeloma: a long‐term single‐centre experience

The role of upfront non‐myeloablative allogeneic stem cell transplantation (NMA alloSCT) in high‐risk multiple myeloma (HR‐MM) is unclear. We evaluated outcomes of NMA alloSCT following autologous stem cell transplant (ASCT) compared with ASCT alone for newly diagnosed HR‐MM. Two‐year progression‐fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Phillip C., Muirhead, Jenny, Tan, Joanne, Kalff, Anna, Bergin, Krystal, Walker, Patricia, Spencer, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543527/
https://www.ncbi.nlm.nih.gov/pubmed/35808923
http://dx.doi.org/10.1111/imj.15842
_version_ 1784804394001235968
author Nguyen, Phillip C.
Muirhead, Jenny
Tan, Joanne
Kalff, Anna
Bergin, Krystal
Walker, Patricia
Spencer, Andrew
author_facet Nguyen, Phillip C.
Muirhead, Jenny
Tan, Joanne
Kalff, Anna
Bergin, Krystal
Walker, Patricia
Spencer, Andrew
author_sort Nguyen, Phillip C.
collection PubMed
description The role of upfront non‐myeloablative allogeneic stem cell transplantation (NMA alloSCT) in high‐risk multiple myeloma (HR‐MM) is unclear. We evaluated outcomes of NMA alloSCT following autologous stem cell transplant (ASCT) compared with ASCT alone for newly diagnosed HR‐MM. Two‐year progression‐free survival was improved in the ASCT‐NMA alloSCT group (44% vs 16%; P = 0.035), with a trend for improved overall survival (P = 0.118). These results suggest that ASCT‐NMA alloSCT can be considered as upfront therapy in HR‐MM.
format Online
Article
Text
id pubmed-9543527
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-95435272022-10-14 Upfront tandem autologous non‐myeloablative allogeneic stem cell transplant in high‐risk multiple myeloma: a long‐term single‐centre experience Nguyen, Phillip C. Muirhead, Jenny Tan, Joanne Kalff, Anna Bergin, Krystal Walker, Patricia Spencer, Andrew Intern Med J Brief Communications The role of upfront non‐myeloablative allogeneic stem cell transplantation (NMA alloSCT) in high‐risk multiple myeloma (HR‐MM) is unclear. We evaluated outcomes of NMA alloSCT following autologous stem cell transplant (ASCT) compared with ASCT alone for newly diagnosed HR‐MM. Two‐year progression‐free survival was improved in the ASCT‐NMA alloSCT group (44% vs 16%; P = 0.035), with a trend for improved overall survival (P = 0.118). These results suggest that ASCT‐NMA alloSCT can be considered as upfront therapy in HR‐MM. John Wiley & Sons Australia, Ltd 2022-07-09 2022-07 /pmc/articles/PMC9543527/ /pubmed/35808923 http://dx.doi.org/10.1111/imj.15842 Text en © 2022 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Brief Communications
Nguyen, Phillip C.
Muirhead, Jenny
Tan, Joanne
Kalff, Anna
Bergin, Krystal
Walker, Patricia
Spencer, Andrew
Upfront tandem autologous non‐myeloablative allogeneic stem cell transplant in high‐risk multiple myeloma: a long‐term single‐centre experience
title Upfront tandem autologous non‐myeloablative allogeneic stem cell transplant in high‐risk multiple myeloma: a long‐term single‐centre experience
title_full Upfront tandem autologous non‐myeloablative allogeneic stem cell transplant in high‐risk multiple myeloma: a long‐term single‐centre experience
title_fullStr Upfront tandem autologous non‐myeloablative allogeneic stem cell transplant in high‐risk multiple myeloma: a long‐term single‐centre experience
title_full_unstemmed Upfront tandem autologous non‐myeloablative allogeneic stem cell transplant in high‐risk multiple myeloma: a long‐term single‐centre experience
title_short Upfront tandem autologous non‐myeloablative allogeneic stem cell transplant in high‐risk multiple myeloma: a long‐term single‐centre experience
title_sort upfront tandem autologous non‐myeloablative allogeneic stem cell transplant in high‐risk multiple myeloma: a long‐term single‐centre experience
topic Brief Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543527/
https://www.ncbi.nlm.nih.gov/pubmed/35808923
http://dx.doi.org/10.1111/imj.15842
work_keys_str_mv AT nguyenphillipc upfronttandemautologousnonmyeloablativeallogeneicstemcelltransplantinhighriskmultiplemyelomaalongtermsinglecentreexperience
AT muirheadjenny upfronttandemautologousnonmyeloablativeallogeneicstemcelltransplantinhighriskmultiplemyelomaalongtermsinglecentreexperience
AT tanjoanne upfronttandemautologousnonmyeloablativeallogeneicstemcelltransplantinhighriskmultiplemyelomaalongtermsinglecentreexperience
AT kalffanna upfronttandemautologousnonmyeloablativeallogeneicstemcelltransplantinhighriskmultiplemyelomaalongtermsinglecentreexperience
AT berginkrystal upfronttandemautologousnonmyeloablativeallogeneicstemcelltransplantinhighriskmultiplemyelomaalongtermsinglecentreexperience
AT walkerpatricia upfronttandemautologousnonmyeloablativeallogeneicstemcelltransplantinhighriskmultiplemyelomaalongtermsinglecentreexperience
AT spencerandrew upfronttandemautologousnonmyeloablativeallogeneicstemcelltransplantinhighriskmultiplemyelomaalongtermsinglecentreexperience

Ejemplares similares